---
title: "Over 2,100 oncology clinical trials initiated globally in 2024, with targeted therapies as fastest growing, over 100..."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276148369.md"
description: "Posted by Oncolytics Biotech Inc. based in Vancouver, BC on February 17, 2026, Equity-Insider.com News Commentary states that in 2024, a total of 2,100 oncology clinical trials were launched worldwide. Among these, targeted therapies emerged as the most rapidly expanding subcategory, with over 100 trials conducted in this area."
datetime: "2026-02-17T16:21:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276148369.md)
  - [en](https://longbridge.com/en/news/276148369.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276148369.md)
---

# Over 2,100 oncology clinical trials initiated globally in 2024, with targeted therapies as fastest growing, over 100...

Posted by Oncolytics Biotech Inc. based in Vancouver, BC on February 17, 2026, Equity-Insider.com News Commentary states that in 2024, a total of 2,100 oncology clinical trials were launched worldwide. Among these, targeted therapies emerged as the most rapidly expanding subcategory, with over 100 trials conducted in this area.

### Related Stocks

- [ONCY.US](https://longbridge.com/en/quote/ONCY.US.md)

## Related News & Research

- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [SNGX: Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data](https://longbridge.com/en/news/282252622.md)
- [Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today](https://longbridge.com/en/news/282724130.md)
- [CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months](https://longbridge.com/en/news/282582813.md)
- [Can XRP Realistically Hit $100?](https://longbridge.com/en/news/282356423.md)